drugset
drugset / Trial / NCT00354198

Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis

NCT00354198 ↗

Phase 3 Terminated 7 enrolled National Taiwan University Hospital National Science and Technology Council, Taiwan · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

We have recently demonstrated that pentoxifylline (PTX) has the potential to treat severe glomerular inflammation in a rat model of accelerated anti-glomerular basement membrane (GBM) glomerulonephritis. This study aims to investigate the therapeutic effects of combined PTX and conventional immunosuppressive regimens on patients with rapidly progressive glomerulonephritis.

Timeline

Start
2006-08
Primary completion
2009-08
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Pentoxifylline Small molecule 0.33 mg/kg Intravenous
Subject Pentoxifylline Small molecule 0.66 mg/kg Intravenous
Subject Pentoxifylline Small molecule 400 mg Intravenous
Subject Pentoxifylline Small molecule 800 mg Intravenous
Background Methylprednisolone Other / unclassified 15 mg/kg Intravenous
Background Methylprednisolone Other / unclassified 1 g Intravenous
Background Prednisolone Other / unclassified 0.5 mg/kg Oral
Background Prednisolone Other / unclassified 1 mg/kg Oral

Indications

glomerulonephritis